ACT-385781A PAH
Phase 3
- Conditions
- Pulmonary arterial hypertension (PAH)
- Registration Number
- JPRN-jRCT1080221971
- Lead Sponsor
- Actelion Pharmaceuticals Japan Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Patients with the following types of pulmonary arterial hypertension (PAH) belonging to Dana Point classification Group I:
Idiopathic (IPAH), Heritable (HPAH), Drugs and toxins induced, or Associated (APAH) with Connective tissue diseases
Exclusion Criteria
Patients with respiratory and/or cardiovascular distress in need of emergency care, Known or suspicion of pulmonary veno-occlusive disease (PVOD), etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AE, Vital sign, Body weight and clinical laboratory test, etc.
- Secondary Outcome Measures
Name Time Method